These 3 Dividend Stocks Jumped 15% in a Month—More to Come?

As the US inventory market continues to drop, traders are turning their consideration to defensive investments. Dividend shares have at all times been an investor favourite when costs begin to drop, offering instant revenue that may probably offset falling costs in different areas.  

Whereas dividend shares often aren’t additionally categorized as development shares, some shares buck this development and mix revenue with constant value appreciation. These 4 dividend shares have seen a share value improve of a minimum of 15% within the final 30 days. Let’s check out what funding analysts need to say about future payout and value potential. 

Gilead Sciences Reveals 20% One-Month Worth Pump

Gilead Sciences (NASDAQ: GILD) is a biopharmaceutical firm targeted on growing and advertising and marketing therapies for liver illnesses, inflammatory illnesses, HIV and extra. It’s additionally considered one of just a few biomedical stocks to supply a dividend, with a present dividend yield of two.72% as of Mar. 11, 2025. Gilead has additionally grown its dividend over time, with a 2.74% annualized three-year development.  

GILD has seen its shares rise by 22% within the final month. A part of this bounce in share costs is as a result of firm’s most up-to-date earnings launch. In the latest quarter, Gilead Sciences reported a $1.90 EPS worth, $0.23 larger than analysts’ estimated $1.67 consensus EPS.  

Latest will increase in institutional investments can also be contributing to larger share costs, with institutional investment purchases rising to $6.53 billion within the fourth quarter of 2024. Whereas insider possession stays exceptionally excessive at 83.67%, analysts stay break up on value targets. Consensus value targets put the inventory at a Average Purchase degree, with a possible draw back of 11% within the subsequent 12 months. 

CVS Proclaims New Openings, Sees Share Costs Rise 

Regardless of closing greater than 1,000 shops earlier this 12 months, nationwide well being and wonder retail chain CVS Health (NYSE: CVS) is seeing share costs rise with its newly introduced reorganization. In keeping with an announcement made to CNN, CVS is planning to open a sequence of smaller shops specializing in pharmaceutical necessities to stay aggressive in opposition to rivals like Amazon.com and Goal.  

This reorganization, in addition to a current earnings announcement shock, has resulted in a 20% value appreciation in CVS shares throughout the final 30 days. The corporate reported an EPS worth of $1.19 on February twelfth, beating estimates of $0.89 per share by greater than 33%. This started the upward development in analyst value targets, with earnings anticipated to develop by a further 15% subsequent 12 months alone. 

CVS is a prime dividend inventory for S&P 500 traders, with a 4.10% dividend yield as of Mar. 11, 2025. Along with a persistently aggressive yield, CVS can be a favourite for traders in search of revenue investments which are capable of sustain with inflation. Its three-year annualized dividend development fee is 9.97%, leading to a payout of about 29% of the corporate’s obtainable money circulation. Nonetheless, before you purchase, word the corporate’s present payout ratio of 72.68%, which may point out a coming lower. 

Verizon Rings in an Exceptionally Excessive Dividend Yield 

The United States‘ largest supplier of cell phone companies, Verizon Communications (NYSE: VZ), catches the eye of analysts every time it reviews earnings. The newest quarter was no exception — and although Verizon barely missed estimates by $0.01 per share, its precise $1.10 EPS was capable of ship costs on a gradual upward development of 16% appreciation within the final 30 days. 

Share costs aren’t the one factor rising with Verizon. The corporate can be a notable decide for long-term dividend will increase, with a 20-year history of elevating payouts. Whereas its annualized three-year development fee of 1.93% is lower than notable contemplating Verizon’s practically $200 billion market cap, this components out to a excessive yield of 6.30% as of Mar. 11, 2025. 

Present dips in U.S. share costs could current a shopping for alternative for dividend traders, no matter VZ’s one-month value spike. The inventory’s P/E ratio stays low at 11.24, which can point out that shares are being oversold on account of market strain. Institutional funding developments help this confidence, with $7.5 billion in shares purchased within the fourth quarter of 2024. 

Corporations Talked about in This Article:

Firm	Present Worth	Worth Change	Dividend Yield	P/E Ratio	Consensus Ranking	Consensus Worth Goal
CVS Well being (CVS)	$65.19	-0.1%	4.08%	17.82	Average Purchase	$69.82
Gilead Sciences (GILD)	$115.28	-1.6%	2.74%	312.05	Average Purchase	$104.52
Verizon Communications (VZ)	$43.11	-7.3%	6.29%	10.41	Average Purchase	$46.11

About Sarah Horvath

Expertise

Sarah Horvath has been a contributing author for DividendStocks.com since 2022.

Areas of Experience

Retirement investing, long-term retail investing, private finance

Training

Bachelor of Arts, Arcadia College, Glenside

Previous Expertise

Vanguard, Nationwide, Benzinga and MarketWatch